Browse

Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
Kim, Gwan-Shik; Kim, Young Hee; Baek, Jeong-Hwa
Issue Date
2002-05
Publisher
Korean Society of Medical Biochemistry
Citation
Experimental and Molecular Medicine 2002;34:145-151
Keywords
RANKLOPGalendronatepamidronateosteoclastogenesis
Abstract
The mechanism of inhibitory action of bisphosphonates on bone resorption is not fully elucidated. Osteoclast formation and activity are regulated by osteoblast-derived factors such as the osteoclast differentiating factor, receptor activator of NF-kappaB ligand (RANKL) and the inhibitor, osteoprotegerin (OPG). To investigate in vitro effects of bisphosphonates on mouse osteoblastic cells, we examined the expression levels of RANKL and OPG in the cells treated with alendronate or pamidronate (10(-8)~10(-5) M) alone, or combined with 10 nM of 1,25-(OH)(2)VitD(3) for 24 or 48 h. Various concentrations of alendronate and pamidronate did not change the mRNA expression of RANKL and OPG consistently irrespective of 1,25-(OH)(2)VitD(3) presence. When added into cocultures of mouse osteoblastic cells and bone marrow cells, both alendronate and pamidronate inhibited osteoclast formation and bone resorption but failed to alter the RANKL and OPG mRNA expression. These results indicate that the inhibition of bone resorption by bisphosphonates is not mediated by the regulation of RANKL and OPG expression.
ISSN
1226-3613
Language
English
URI
http://hdl.handle.net/10371/68604
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Dentistry/School of Dentistry (치과대학/치의학대학원)Dept. of Dentistry (치의학과)Journal Papers (저널논문_치의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse